Dipropylamphetamin | 59313-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Dipropylamphetamin
• 英文别名: N,N-di-n-propylamphetamine；Di-n-propylamphetamin；N,N-Dipropylamphetamine；1-phenyl-N,N-dipropylpropan-2-amine
• CAS: 59313-93-8
• 化学式: C₁₅H₂₅N
• 分子量: 219.37
• InChiKey: COGKMFLJJLBANK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Dipropylamphetamin 生成 D-N-丙基安非他命
  参考文献：
  名称：

  药物代谢和处置中的定量构效关系：N-取代的苯丙胺在人体中的药代动力学

  摘要：

  人体中15种N-烷基取代的苯丙胺的药代动力学数据一直是回顾性定量构效关系研究的对象。苯丙胺的尿排泄随着亲脂性的增加而减少。相关方程表明，对于相同的亲脂性，叔胺的排泄速度要快于仲胺，仲胺的排泄速度要快于伯胺。表观的正庚烷-pH 7.4缓冲液分配系数与尿液排泄的关系比真实的正辛醇-水分配系数的相关性更好，这可能是因为它包含一个pKa项，该术语说明了作为非离子物质存在于肾小管中的药物比例。

  DOI：

  10.1002/jps.2600690505

文献信息

• Sulfur(VI) fluoride compounds and methods for the preparation thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10765645B2

  公开（公告）日：2020-09-08

  This application describes a compound represented by Formula (I): YZX1—S(O)(X2)F)m]n  (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

  本申请描述了一种由式 (I) 表示的化合物： YZX1-S(O)(X2)F)m]n (I) 其中Y 是生物活性有机核心基团，包括芳基、杂芳基、非芳香烃基和非芳香杂环基中的一个或多个，Z 与之共价键合；n 是 1、2、3、4 或 5；m 是 1 或 2；Z是O、NR或N；X1是共价键或-CH2CH2-，X2是O或NR；R包括H或选自芳基、杂芳基、非芳香烃基和非芳香杂环基的取代或未取代基团。此外，还描述了制备这些化合物的方法、使用这些化合物的方法以及包含这些化合物的药物组合物。
• SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20200397719A1

  公开（公告）日：2020-12-24

  This application describes a compound represented by Formula (I): wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X 1 is a covalent bond or —CH 2 CH 2 —, X 2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.
• Quantitative structure–activity relationships in drug metabolism and disposition: Pharmacokinetics of N-substituted amphetamines in humans
  作者：Bernard Testa、Bjarne Salvesen

  DOI：10.1002/jps.2600690505

  日期：1980.5

  Pharmacokinetic data of 15 N-alkyl-substituted amphetamines in humans have been the object of a retrospective quantitative structure-activity relationship study. The urinary excretion of amphetamines was shown to decrease with increasing lipophilicity; the correlation equations revealed that, for identical lipophilicities, tertiary amines are excreted faster than secondary amines, which are excreted

  人体中15种N-烷基取代的苯丙胺的药代动力学数据一直是回顾性定量构效关系研究的对象。苯丙胺的尿排泄随着亲脂性的增加而减少。相关方程表明，对于相同的亲脂性，叔胺的排泄速度要快于仲胺，仲胺的排泄速度要快于伯胺。表观的正庚烷-pH 7.4缓冲液分配系数与尿液排泄的关系比真实的正辛醇-水分配系数的相关性更好，这可能是因为它包含一个pKa项，该术语说明了作为非离子物质存在于肾小管中的药物比例。